Literature DB >> 31527133

Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma.

Lynda Vuong1,2, Ritesh R Kotecha3, Martin H Voss3, A Ari Hakimi4,5.   

Abstract

Renal cell carcinoma stands out as one of the most immune-infiltrated tumors in pan-cancer comparisons. Features of the tumor microenvironment heavily affect disease biology and may affect responses to systemic therapy. With evolving frontline options in the metastatic setting, several immune checkpoint blockade regimens have emerged as efficacious, and there is growing interest in characterizing features of tumor biology that can reproducibly prognosticate patients and/or predict the likelihood of their deriving therapeutic benefit. Herein, we review pertinent characteristics of the tumor microenvironment with dedicated attention to candidate prognostic and predictive signatures as well as possible targets for future drug development. SIGNIFICANCE: Tumor microenvironment features broadly characterizing angiogenesis and inflammatory signatures have shown striking differences in response to immune checkpoint blockade and antiangiogenic agents. Integration of stromal and immune biomarkers may hence produce predictive and prognostic signatures to guide management with existing regimens as well as future drug development. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31527133      PMCID: PMC6774890          DOI: 10.1158/2159-8290.CD-19-0499

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  71 in total

1.  A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Authors:  Deng Pan; Aya Kobayashi; Peng Jiang; Lucas Ferrari de Andrade; Rong En Tay; Adrienne M Luoma; Daphne Tsoucas; Xintao Qiu; Klothilda Lim; Prakash Rao; Henry W Long; Guo-Cheng Yuan; John Doench; Myles Brown; X Shirley Liu; Kai W Wucherpfennig
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

2.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Authors:  Diana Miao; Claire A Margolis; Wenhua Gao; Martin H Voss; Wei Li; Dylan J Martini; Craig Norton; Dominick Bossé; Stephanie M Wankowicz; Dana Cullen; Christine Horak; Megan Wind-Rotolo; Adam Tracy; Marios Giannakis; Frank Stephen Hodi; Charles G Drake; Mark W Ball; Mohamad E Allaf; Alexandra Snyder; Matthew D Hellmann; Thai Ho; Robert J Motzer; Sabina Signoretti; William G Kaelin; Toni K Choueiri; Eliezer M Van Allen
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

3.  Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment.

Authors:  Roberto Tamma; Monica Rutigliano; Giuseppe Lucarelli; Tiziana Annese; Simona Ruggieri; Eliano Cascardi; Anna Napoli; Michele Battaglia; Domenico Ribatti
Journal:  Urol Oncol       Date:  2019-02-06       Impact factor: 3.498

4.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.

Authors:  Samira A Brooks; A Rose Brannon; Joel S Parker; Jennifer C Fisher; Oishee Sen; Michael W Kattan; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; C Ryan Miller; Matthew E Nielsen; W Kimryn Rathmell
Journal:  Eur Urol       Date:  2014-02-25       Impact factor: 20.096

5.  Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.

Authors:  Ashley Orillion; Ayumi Hashimoto; Nur Damayanti; Li Shen; Remi Adelaiye-Ogala; Sreevani Arisa; Sreenivasulu Chintala; Peter Ordentlich; Chingai Kao; Bennett Elzey; Dmitry Gabrilovich; Roberto Pili
Journal:  Clin Cancer Res       Date:  2017-07-11       Impact factor: 12.531

Review 6.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Authors:  Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

7.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

8.  An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.

Authors:  A Ari Hakimi; Ed Reznik; Chung-Han Lee; Chad J Creighton; A Rose Brannon; Augustin Luna; B Arman Aksoy; Eric Minwei Liu; Ronglai Shen; William Lee; Yang Chen; Steve M Stirdivant; Paul Russo; Ying Bei Chen; Satish K Tickoo; Victor E Reuter; Emily H Cheng; Chris Sander; James J Hsieh
Journal:  Cancer Cell       Date:  2016-01-11       Impact factor: 31.743

9.  CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Authors:  Ranjana Advani; Ian Flinn; Leslie Popplewell; Andres Forero; Nancy L Bartlett; Nilanjan Ghosh; Justin Kline; Mark Roschewski; Ann LaCasce; Graham P Collins; Thu Tran; Judith Lynn; James Y Chen; Jens-Peter Volkmer; Balaji Agoram; Jie Huang; Ravindra Majeti; Irving L Weissman; Chris H Takimoto; Mark P Chao; Sonali M Smith
Journal:  N Engl J Med       Date:  2018-11-01       Impact factor: 91.245

10.  Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study.

Authors:  Qingbo Yin; Sheng-Che Hung; Li Wang; Weili Lin; Julia R Fielding; W Kimryn Rathmell; Amir H Khandani; Michael E Woods; Matthew I Milowsky; Samira A Brooks; Eric M Wallen; Dinggang Shen
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

View more
  80 in total

1.  Sequential treatment of metastatic renal cancer in a complex evolving landscape.

Authors:  Javier C Angulo; Charles H Lawrie; José I López
Journal:  Ann Transl Med       Date:  2019-12

2.  Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.

Authors:  Raphaëlle Toledano Zur; Galit Adler; Katerina Shamalov; Yair Tal; Chen Ankri; Cyrille J Cohen
Journal:  Exp Suppl       Date:  2022

3.  Establishment and Validation of an Interferon-Stimulated Genes (ISGs) Prognostic Signature in Pan-cancer Patients: A Multicenter, Real-world Study.

Authors:  Zheng Zhou; Yujia Zheng; Shaobo Mo; Shuofeng Li; Xinlei Zheng; Ran Wei; Tao Fan; Tianli Chen; Chu Xiao; Chunxiang Li; Jie He
Journal:  Int J Biol Sci       Date:  2022-05-21       Impact factor: 10.750

4.  Comprehensive analysis of immune ferroptosis gene in renal clear cell carcinoma: prognosis and influence of tumor microenvironment.

Authors:  Lin-Hui Yang; Li-Zhen Xu; Zhi-Jian Huang; Hong-Hong Pan; Min Wu; Qiu-Yan Wu; Tao Lu; Yan-Ping Zhang; Yao-Bin Zhu; Jia-Bin Wu; Jie-Wei Luo; Guo-Kai Yang; Lie-Fu Ye
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 5.  Cancer-associated fibroblasts: overview, progress, challenges, and directions.

Authors:  Qinrong Ping; Ruping Yan; Xin Cheng; Wenju Wang; Yiming Zhong; Zongliu Hou; Yunqiang Shi; Chunhui Wang; Ruhong Li
Journal:  Cancer Gene Ther       Date:  2021-03-12       Impact factor: 5.987

Review 6.  Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review.

Authors:  Yoon-Soo Hah; Kyo-Chul Koo
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

7.  Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review).

Authors:  Danhua Wang; Yiwen Sang; Tao Sun; Piaoping Kong; Lingyu Zhang; Yibei Dai; Ying Cao; Zhihua Tao; Weiwei Liu
Journal:  Int J Oncol       Date:  2021-03-24       Impact factor: 5.650

8.  Evaluation of the morphological features and unfavorable prognostic impact of dirty necrosis in renal cell carcinoma.

Authors:  Takashi Kuroe; Reiko Watanabe; Motohiro Kojima; Ryo Morisue; Masato Sugano; Takeshi Kuwata; Hitoshi Masuda; Shota Kusuhara; Nobuaki Matsubara; Shioto Oda; Tetsuo Ushiku; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-21       Impact factor: 4.553

Review 9.  Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.

Authors:  Hye-Won Lee
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

10.  Prognostic Roles of Phosphofructokinase Platelet in Clear Cell Renal Cell Carcinoma and Correlation with Immune Infiltration.

Authors:  Bin Liu; Faping Li; Mingdi Liu; Zhixiang Xu; Baoshan Gao; Yishu Wang; Honglan Zhou
Journal:  Int J Gen Med       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.